[{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Madrigal Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"ADX-1612","moa":"Heat shock protein HSP90","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Madrigal Pharmaceuticals \/ Madrigal Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Madrigal Pharmaceuticals \/ Madrigal Pharmaceuticals"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"ADX-1612","moa":"Heat shock protein HSP90","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Madrigal Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Madrigal Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"ADX-1612","moa":"Heat shock protein HSP90","graph1":"Oncology","graph2":"Phase II","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Madrigal Pharmaceuticals \/ Madrigal Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Madrigal Pharmaceuticals \/ Madrigal Pharmaceuticals"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"ADX-1612","moa":"Heat shock protein HSP90","graph1":"Oncology","graph2":"Phase I","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Madrigal Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Madrigal Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"ADX-1612","moa":"Heat shock protein HSP90","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Madrigal Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Madrigal Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"ADX-1612","moa":"Heat shock protein HSP90","graph1":"Oncology","graph2":"Phase II","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Madrigal Pharmaceuticals \/ Madrigal Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Madrigal Pharmaceuticals \/ Madrigal Pharmaceuticals"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"ADX-1612","moa":"Heat shock protein HSP90","graph1":"Oncology","graph2":"Phase II","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Madrigal Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Madrigal Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Dana-Farber Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"ADX-1612","moa":"Heat shock protein HSP90","graph1":"Oncology","graph2":"Phase II","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Madrigal Pharmaceuticals \/ Madrigal Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Madrigal Pharmaceuticals \/ Madrigal Pharmaceuticals"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Madrigal Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"ADX-1612","moa":"Heat shock protein HSP90","graph1":"Oncology","graph2":"Phase I","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Madrigal Pharmaceuticals \/ Madrigal Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Madrigal Pharmaceuticals \/ Madrigal Pharmaceuticals"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Celerion","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Atorvastatin","moa":"HMG-CoA reductase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Madrigal Pharmaceuticals \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Madrigal Pharmaceuticals \/ Celerion"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Celerion","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Simvastatin","moa":"HMG-CoA reductase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Madrigal Pharmaceuticals \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Madrigal Pharmaceuticals \/ Celerion"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2011","type":"Inapplicable","leadProduct":"Elesclomol Sodium","moa":"Mitochondria","graph1":"Oncology","graph2":"Phase I","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Madrigal Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Madrigal Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Madrigal Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Capecitabine","moa":"RNA | DNA | Thymidylate synthase","graph1":"Oncology","graph2":"Phase I","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Madrigal Pharmaceuticals \/ Madrigal Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Madrigal Pharmaceuticals \/ Madrigal Pharmaceuticals"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Resmetirom","moa":"Thyroid hormone receptor beta-1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Madrigal Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Madrigal Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Resmetirom","moa":"Thyroid hormone receptor beta-1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Madrigal Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Madrigal Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Celerion","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Resmetirom","moa":"Thyroid hormone receptor beta-1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Madrigal Pharmaceuticals \/ Celerion"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Resmetirom","moa":"Thyroid hormone receptor beta-1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Madrigal Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Resmetirom","moa":"Thyroid hormone receptor beta-1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Madrigal Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Worldwide Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Resmetirom","moa":"Thyroid hormone receptor beta-1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"6","companyTruncated":"Madrigal Pharmaceuticals \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Resmetirom","moa":"Thyroid hormone receptor beta-1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Madrigal Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Resmetirom","moa":"Thyroid hormone receptor beta-1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Madrigal Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Resmetirom","moa":"Thyroid hormone receptor beta-1","graph1":"Nephrology","graph2":"Phase I","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Madrigal Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Resmetirom","moa":"Thyroid hormone receptor beta-1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Madrigal Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Resmetirom","moa":"Thyroid hormone receptor beta-1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Madrigal Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Resmetirom","moa":"Thyroid hormone receptor beta-1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Madrigal Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Resmetirom","moa":"Thyroid hormone receptor beta-1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Madrigal Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Resmetirom","moa":"Thyroid hormone receptor beta-1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Madrigal Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Resmetirom","moa":"Thyroid hormone receptor beta-1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Madrigal Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Resmetirom","moa":"Thyroid hormone receptor beta-1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Madrigal Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"Resmetirom","moa":"Thyroid hormone receptor beta-1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Madrigal Pharmaceuticals","amount2":0.59999999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0.59999999999999998,"dosageForm":"Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Goldman Sachs & Co","highestDevelopmentStatusID":"15","companyTruncated":"Madrigal Pharmaceuticals \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Resmetirom","moa":"Thyroid hormone receptor beta-1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Madrigal Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Resmetirom","moa":"Thyroid hormone receptor beta-1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Madrigal Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Resmetirom","moa":"Thyroid hormone receptor beta-1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Madrigal Pharmaceuticals","amount2":0.5,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0.59999999999999998,"dosageForm":"Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Goldman Sachs & Co","highestDevelopmentStatusID":"15","companyTruncated":"Madrigal Pharmaceuticals \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Hercules Credit Facility","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Financing","leadProduct":"Resmetirom","moa":"Thyroid hormone receptor beta-1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Madrigal Pharmaceuticals","amount2":0.26000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0.26000000000000001,"dosageForm":"Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Hercules Credit Facility","highestDevelopmentStatusID":"15","companyTruncated":"Madrigal Pharmaceuticals \/ Hercules Credit Facility"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Resmetirom","moa":"Thyroid hormone receptor beta-1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Madrigal Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Resmetirom","moa":"Thyroid hormone receptor beta-1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Madrigal Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Resmetirom","moa":"Thyroid hormone receptor beta-1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Madrigal Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Resmetirom","moa":"Thyroid hormone receptor beta-1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Madrigal Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Resmetirom","moa":"Thyroid hormone receptor beta-1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Madrigal Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Resmetirom","moa":"Thyroid hormone receptor beta-1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Madrigal Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Resmetirom","moa":"Thyroid hormone receptor beta-1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Madrigal Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Resmetirom","moa":"Thyroid hormone receptor beta-1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Madrigal Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Resmetirom","moa":"Thyroid hormone receptor beta-1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Madrigal Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Resmetirom","moa":"Thyroid hormone receptor beta-1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Madrigal Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Resmetirom","moa":"Thyroid hormone receptor beta-1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Madrigal Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Resmetirom","moa":"Thyroid hormone receptor beta-1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Madrigal Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Madrigal Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Resmetirom","moa":"Thyroid hormone receptor beta-1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Madrigal Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Madrigal Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Resmetirom","moa":"Thyroid hormone receptor beta-1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Madrigal Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Madrigal Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Resmetirom","moa":"Thyroid hormone receptor beta-1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Madrigal Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Madrigal Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Resmetirom","moa":"Thyroid hormone receptor beta-1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Madrigal Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Madrigal Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2013","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Madrigal Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Madrigal Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"David M. Jackman","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"ADX-1612","moa":"Heat shock protein HSP90","graph1":"Oncology","graph2":"Phase II","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Madrigal Pharmaceuticals \/ David M. Jackman","highestDevelopmentStatusID":"8","companyTruncated":"Madrigal Pharmaceuticals \/ David M. Jackman"}]
Find Clinical Drug Pipeline Developments & Deals by Madrigal Pharmaceuticals
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
